Salient Pharma ApS: Financial statements 2022
CVR: 36900709
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -125,514 and a net result of DKK -188,162 compared with DKK -301,256 the year before. Equity in the 2022 report amounted to DKK -981,365.
- Gross Profit
- DKK -125,514
- Profit/Loss
- DKK -188,162
- Equity
- DKK -981,365
- Total Assets
- DKK 58,007
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -126 t. | -188 t. | -981 t. | 0 |
| 2021 | - | -259 t. | -301 t. | -793 t. | 0 |
| 2020 | - | -485 t. | -902 t. | -492 t. | 1 |
| 2019 | - | -730 t. | -2.4 mio. | 410 t. | 1 |
| 2018 | - | -838 t. | -710 t. | 2.8 mio. | - |
Official annual report
Keep an eye on Salient Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Salient Pharma ApS has published its annual report for 2021. Gross profit came to DKK -259,487, and the net result was DKK -301,256.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The board consists of Helle Bøwadt, Søren Wang Petersen and Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity in the 2025 report amounted to DKK -1,344,010.